An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
← catalyst calendarNCT03936335 · readout in 155 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →. With Sanofi.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
3,930estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-09-30 | actual | When the study began enrolling |
| Primary completion | 2027-01-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-21 | estimated | The whole study's end, after follow-up |
| First posted | 2019-05-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Adverse Pregnancy Outcomes
- Atopic Dermatitis
Intervention
- Drug: dupilumab — also filed as REGN668, Dupixent®, SAR23189
Primary outcome
what the primary-completion date above is the date OFPrevalence of MCMs
measured Up to 21 months
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed